Efficacy and safety of switching from angiotensin II receptor blocker-diuretic combinations therapy to combination tablets (candesartan cilexetil-hydrochlorothiazide) in hypertension.
Not Applicable
- Conditions
- Hypertensive patients receiving combined therapy with candesartan cilexetil and diuretic
- Registration Number
- JPRN-UMIN000003417
- Lead Sponsor
- Kanazawa Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient who is anuric and/or dialysis 2.Patient with ARF (acute renal failure) 3.Patient with sodium - and potassium - depletion / sodium - and potassium - depleted patients 4.Patient who is pregnant or possibly pregnant 5.Patients with a history of hypersensitivity to ingredients of Ecard HD (candesartan cilexetil-hydrochlorothiazide) or other thiazide or thiazide-like diuretics 6.Patient who is determined to be excluded from the study due to any reason by the study doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Change in blood pressure (absolute value) 2.Changes in uric acid (absolute value)
- Secondary Outcome Measures
Name Time Method 1.TC, TG, HDL-C 2.BNP 3.cystatin C 4.blood glucose level (HbA1c, fasting blood sugar) 5.urinary albumin, urinary sodium 6.safety : serum potassium